SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping the future of healthcare and medical innovation. MOUNT PLEASANT, S.C., Oct. 14, 2026 /PRNewswire/ -- Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on transforming care for rare diseases, today announced it has been named a finalist for the 2026 Prix Galien USA "Be…READ FULL ARTICLE